Comparative Pharmacology
Head-to-head clinical analysis: ANCEF versus CEFOTAXIME AND DEXTROSE 3 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF versus CEFOTAXIME AND DEXTROSE 3 9 IN PLASTIC CONTAINER.
ANCEF vs CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
1-2 g IV/IM every 8 hours; maximum 6 g/day.
1-2 g IV every 4-6 hours; maximum 12 g/day.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolongs significantly in renal impairment (up to 30 hours in anuria).
Terminal elimination half-life: 0.8-1.4 hours in adults with normal renal function; prolonged to 2.5-15 hours in renal impairment; clinical context: dosing interval adjustment required for CrCl <20 mL/min
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); small amounts biliary (<1%) and fecal.
Primarily renal (80-90% unchanged within 24 hours); biliary/fecal elimination accounts for <10%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic